Personalized mRNA Tumor Vaccine (Changhai Hospital)

The personalized mRNA tumor vaccine is an investigational immunotherapy developed by Changhai Hospital (Naval Medical University, Shanghai) in collaboration with Stemirna Therapeutics for the treatment of advanced gastrointestinal cancers. Utilizing a patient-specific approach, the vaccine is designed based on whole exome sequencing (WES) and RNA sequencing of an individual's tumor to identify unique somatic mutations. It encodes up to 20 tumor-specific neoantigens, which are delivered via mRNA to stimulate a robust T-cell immune response against the cancer cells. The vaccine is administered subcutaneously and is currently being evaluated in Phase I/II clinical trials (notably NCT03468244) for patients with esophageal squamous cell carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, and colorectal adenocarcinoma who have progressed after standard first-line chemotherapy.

Other names

personalized mRNA tumor vaccine-Changhai Hospital-esophageal squamous cell carcinoma-gastric adenocarcinoma-pancreatic adenocarcinoma-colorectal adenocarcinomaPersonalized mRNA neoantigen vaccinemRNA-based neoantigen vaccine